Tiziana life sciences announces completion of prerequisite pre-clinical safety study

New york, dec. 15, 2022 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces completion of the in-life portion of a 13-week, good laboratory practice (glp) foralumab intranasal pre-clinical study in transgenic hugemm cd3 mouse models. the study showed that intranasal foralumab, administered to the transgenic mice at doses up to 50 Μg/rodent, was clinically well tolerated.
TLSA Ratings Summary
TLSA Quant Ranking